SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise® MRD test. Research collaborations include: A study to determine whether circulating tumor DNA (ctDNA) level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive ...

Core Insights - Myriad Genetics and Ultima Genomics have announced a collaboration to utilize Ultima's UG 100™ sequencing platform and ppmSeq™ technology to enhance Myriad's clinical testing capabilities [1][2][3] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [4] - Ultima Genomics aims to revolutionize genomic sequencing by providing low-cost, high-throughput sequencing solutions that can scale beyond conventional technologies [5] Technological Advancements - The UG 100 platform is expected to provide low-cost and low-error sequencing, which will benefit Myriad's emerging products, particularly the Precise Molecular Residual Disease (MRD) test and the FirstGene Multiple Prenatal Screen [2][3] - Myriad's Precise MRD test will utilize whole-genome sequencing to identify tumor-specific variants, enhancing personalized tracking for cancer patients [2] - The FirstGene Multiple Prenatal Screen will streamline multiple prenatal tests into a single sequencing workflow, requiring deep and accurate sequencing capabilities [2] Strategic Goals - Myriad's collaboration with Ultima is aimed at making cutting-edge genetic testing more accessible and affordable, with the UG 100 potentially lowering costs and improving quality for their tests [3] - The partnership is expected to facilitate the exploration of new product areas that may have been previously challenging due to high sequencing costs [3]

Core Insights - Myriad Genetics has received a third patent for its tumor-informed, high-definition molecular residual disease (MRD) assay, enhancing its market capabilities [1][2] - The new patent, U.S. patent no. 12,104,212, focuses on personalized methods for detecting circulating tumor DNA (ctDNA), showcasing Myriad's commitment to advancing its MRD strategy [1][2] - The Precise MRD assay is designed to track thousands of tumor-specific variants, allowing for lower-level ctDNA detection compared to existing market products [2] Company Developments - Myriad Genetics is leveraging its existing technology, including the FDA-approved MyChoice® CDx and FirstGeneTM platforms, to develop the Precise MRD assay [2] - The company is conducting high-impact studies for the Precise MRD assay and transitioning to a new laboratory facility in Salt Lake City [2] - Collaborations for MRD studies include partnerships with Memorial Sloan Kettering, The University of Texas MD Anderson Cancer Center, and the National Cancer Center Hospital East in Japan [2][3] Industry Context - The MRD market is characterized as emerging and under-penetrated, presenting significant opportunities for Myriad to advance oncology care [2] - Myriad Genetics aims to commercialize the Precise MRD assay profitably, addressing the needs of cancer patients and biopharma companies [2]

Myriad Genetics, Inc. (MYGN) is making notable strides in its key strategic areas, which is poised to help it grow in the upcoming quarters. New product introductions and enhancements are gaining traction with customers. There is growing optimism about the company’s huge potential in the oncology space. Meanwhile, the impacts of macroeconomic pressure and fierce rivalry can be worrisome for Myriad Genetics’ performance.In the past year, this Zacks Rank #3 (Hold) company has outperformed both the industry an ...

Myriad Genetics (MYGN) has been gaining share in the hereditary cancer market, with volumes rising 3% year over year in the second quarter of 2024. The company continues to see momentum in its prenatal business as well, growing 25% year over year with a 12% increase in testing volume. This volume growth reflects ongoing initiatives to improve average selling prices (ASPs). The stock carries a Zacks Rank #3 (Hold) currently.The company continues to enhance its customer targeting, digital marketing, and overa ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences. The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET. L ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President-Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Colleen Babington - Wolfe Research Andrew Cooper - Raymond James Casey Woodring - JPMorgan Puneet Souda - Leerink Partner ...

| --- | --- | --- | --- | |------------------------------------|-------|-------|-------| | | | | | | A U G U S T 6 , 2 0 2 4 | | | | | | | | | | | | | | | Second Quarter 2024 Earnings Call | | | | | | | | | ©2024 Myriad Genetics, Inc. ©2024 Myriad Genetics, Inc. Forward-looking statements and Non-GAAP financial measures Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOK ...

Myriad Genetics, Inc. (MYGN) reported adjusted earnings of 5 cents per share in the second quarter of 2024 compared to the Zacks Consensus Estimate of a loss of 1 cent per share. The reported figure also compares to a loss of 8 cents per share in the year-ago quarter.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization, among others.RevenuesTotal revenues rose 15.3% year over year to $211.5 million in the quarter under rev ...